The results demonstrated the concurrent expression of both Mcl 1 and

The widths of wound were mea sured and photographed under a phase contrast micro scope. Each experiment was performed in triplicate wells KU-55933 ATM 阻害剤 for three times. Statistical analysis The SPSS statistical package was used for data analysis. Independent sample t and χ2 tests were used to analyze continuous and categorical vari ables, respectively. The risk of MT1G hypermethylation to clinicopathological characteristics was analyzed using uni variate or multivariate logistic regression. All of the statis tical tests were two sided. A P 0. 05 was considered to be statistically significant. Results Frequent down regulation and promoter hypermethylation of MT1G in primary thyroid cancers Similar to the findings in a previous study, MT1G expression was significantly down regulated in PTC tis sues compared with non malignant tissues.<br><br> It has been well doc umented that aberrant promoter methylation is related to gene silencing. We next analyzed the methylation sta tus of MT1G by Linifanib AL-39324 methylation specific PCR. A typ ical CpG island spans the promoter region of MT1G, and the position of MSP primers is indicated in. MT1G hypermathylation was found in 30. 2% of thyroid cancers, includ ing 31. 5% of PTC, 25. 0% of FTC, 22. 2% of MTC, and 22. 2% of ATC. In addition, it was also found in 18. 8% of goiter. These data sug gested that MT1G was more frequently methylated in thyroid cancer tissues compared with non malignant thyroid tissues. MSP results of 2 representative PTC samples were shown in.<br><br> Association of MT1G hypermethylation with lymph node metastasis in PTC Because frequent MT1G hypermethylation was demon strated in thyroid cancers, particularly in PTC, the associ ation of MT1G hypermethylation with LY294002 分子量 clinicopathological characteristics was analyzed in a total of 178 PTC. As shown in Table 2, we failed to find a significant relation ship between MT1G hypermethylation and most of clini copathological characteristics, such as gender, age, tumor invasion, tumor stage, tumor size, and tumor recurrence. However, the univariate analysis revealed that MT1G hypermethylation was associated with a significantly in creased risk of lymph node metastasis. In order to assess the inde pendent association of MT1G hypermethylation with gen der, age, tumor invasion, lymph node metastasis, tumor stage, and tumor recurrence, we further performed multi variate logistic regression.<br><br> Similar to univariate analysis, after adjustment, MT1G hypermethylation remained significantly positively associated with lymph node metastasis. suggesting that MT1G hypermethylation might be an independent factor in predicting lymph node metastasis for PTC patients. Epigenetic silencing of MT1G in thyroid cancer cells To determine whether MT1G expression is regulated by epigenetic mechanisms in thyroid cancer, such as pro moter methylation and histone modification, we exam ined MT1G expression in 6 thyroid cancer cell lines by conventional RT PCR. As shown in Figure 1A, MT1G expression was silenced or down regulated in all thyroid cancer cell lines compared with normal thy roid epithelial cell line HTori3. MT1G hypermethylation combination with 5 Aza dC.